Apontis Pharma AG gross margin has been in long-term decline. The average rate of decline per year is -3.6%.
The historical rank and industry rank for Apontis Pharma AG's Gross Margin % or its related term are showing as below:
FRA:APPH'
s Gross Margin % Range Over the Past 10 Years
Min: 57.16 Med: 63.28 Max: 72.37
Current: 58.16
During the past 7 years, the highestGross Margin % of Apontis Pharma AG was 72.37%. The lowest was 57.16%. And the median was 63.28%.
FRA:APPH's Gross Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 48.44
vs FRA:APPH: 58.16
Apontis Pharma AG had a gross margin of 62.51% for the quarter that ended in Jun. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Apontis Pharma AG was -3.60% per year.
Apontis Pharma AG (FRA:APPH) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Apontis Pharma AG had a gross margin of 62.51% for the quarter that ended in Jun. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Apontis Pharma AG Gross Margin % Related Terms
Apontis Pharma AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:APPH vs ZTS, UTHR, NBIX: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Apontis Pharma AG (FRA:APPH) has a Gross Margin % of 62.51% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Apontis Pharma AG and its competitors. This is near median its historical median of 63.28. Over the past decade, Apontis Pharma AG's Gross Margin % has ranged from 57.16 to 72.37.
Is Apontis Pharma AG's Gross Margin % too high?
Apontis Pharma AG's current Gross Margin % of 62.51% is near median its 10-year median of 63.28. Over the past 10 years, this metric has ranged from a low of 57.16 to a high of 72.37. The Drug Manufacturers industry median Gross Margin % is 48.44. Apontis Pharma AG's value of 62.51% is 29% above this industry median. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's Gross Margin % compare to ZTS and UTHR?
Apontis Pharma AG's Gross Margin % of 62.51% can be compared against companies in the Drug Manufacturers industry. The industry median Gross Margin % is 48.44. Apontis Pharma AG's value of 62.51% is 29% above this benchmark. Historically, Apontis Pharma AG's own Gross Margin % has ranged from 57.16 to 72.37 over the past decade. While the company's 10-year median is 63.28 vs. the industry median of 48.44, Apontis Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apontis Pharma AG's current Gross Margin % of 62.51% is 29% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current Gross Margin % is 62.51%, which is near median its own 10-year median of 63.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current Gross Margin % of 62.51%. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current Gross Margin % is 62.51%, which is near median its 10-year median of 63.28 and 29% above the Drug Manufacturers industry median of 48.44. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current Gross Margin % is 62.51% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
Gross Margin %: 62.51% (near median its 10-year median of 63.28)
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
Industry Position: 29% above the Drug Manufacturers median
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
